ASCENTAGE PHARMA GROUP INTERNATIONAL |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.45 HKD | -2.40% |
|
+6.07% | -10.44% |
| Jun. 18 | Ascentage Pharma Group International Present Results from Three Studies at EHA 2024 | MT |
| Jun. 18 | Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib | CI |
Ascentage Pharma Group International is an investment holding company principally engaged in developing novel small therapies for cancers, hepatitis B virus (HBV) and certain age-related diseases. The Company focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company's main products include the next-generation kinase inhibitor: HQP1351 and apoptosis targeted drugs APG-1252, APG2575, APG-115 and so on. The Company conducts businesses within the domestic market and to overseas markets, including the United States.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
23.31
CNY
Average target price
27.6
CNY
Spread / Average Target
+18.40%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -10.44% | 963M | |
| +15.85% | 121B | |
| +18.91% | 112B | |
| +4.43% | 22.57B | |
| -18.63% | 20.82B | |
| -13.76% | 16.3B | |
| -16.61% | 16.19B | |
| -43.53% | 16.17B | |
| +1.75% | 13.17B | |
| +28.07% | 11.11B |
- Stock Market
- Equities
- 6855 Stock
- News Ascentage Pharma Group International
- Ascentage Pharma CFO Resigns; Shares Fall 5%
